EASI-75
Sanofi Phase 3 Eczema Win Falls Short of Analyst Expectations
Sanofi; amlitelimab; phase 3 trial; eczema; atopic dermatitis; analyst expectations; Dupixent; EASI-75; market reaction
Actionable Insights Powered by AI
Sanofi; amlitelimab; phase 3 trial; eczema; atopic dermatitis; analyst expectations; Dupixent; EASI-75; market reaction